- Telehealth Visits
- Insurance plan information
Javid Moslehi, MD
He | Him | HisCardiology • Cardio-OncologyChief, Cardio-Oncology and Immunology- Telehealth Visits
- Insurance plan information
Javid Moslehi, MD
He | Him | HisCardiology • Cardio-OncologyChief, Cardio-Oncology and Immunology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Javid Moslehi is a cardiologist who specializes in the cardiovascular health of cancer patients, cancer survivors and patients with immunological or metabolic problems that affect cardiovascular health. He serves as chief of UCSF's cardio-oncology and immunology section.
Moslehi's research focuses on how diseases of the cardiovascular system impact cancer patients and survivors. He is also interested in inflammatory heart conditions, such as myocarditis.
Moslehi earned his medical degree from the University of Connecticut School of Medicine. He completed a residency in internal medicine at the Johns Hopkins Hospital. At Brigham and Women's Hospital, he completed a fellowship in cardiology and a postdoctoral research fellowship in oncology. His career includes directing cardio-oncology programs at the Dana-Farber Cancer Institute and Vanderbilt University Medical Center. He is the UCSF William Grossman Distinguished Professor in Cardiology.
Education & training
Board certification
- Cardiovascular Disease, American Board of Internal Med/Cardiovascular Dis
Fellowship
- Cardiovascular Disease, Brigham & Women's Hospital
Residency
- Internal Medicine, Johns Hopkins Univ School of Medicine - Int Med
Internship
- Internal Medicine, Johns Hopkins Univ School of Medicine - Int Med
Degree
- MD, University of Connecticut School of Medicine
My expertise
Specialties
Locations
My research
Publications
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.